Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF +3.12%46 Net Cash per Share is $3.53 as of Dec. 2025, which is 41% below its 10-year median of 5.99. GuruFocus rates CANF with a GF Score™ of 46/100 and a GF Value™ of $6.10 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 796 Biotechnology companies, Can Fite Biopharma ranks better than 92.09% on this metric.
Can Fite Biopharma (AMEX:CANF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Can Fite Biopharma Net Cash per Share Related Terms
Can Fite Biopharma Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Can Fite Biopharma's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a Net Cash per Share of $3.53 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Can Fite Biopharma and its competitors. This is 41% below median its historical median of 5.99. Over the past decade, Can Fite Biopharma's Net Cash per Share has ranged from 0.95 to 30.51. According to the industry distribution chart, Can Fite Biopharma ranks #63 out of 796 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Can Fite Biopharma's Net Cash per Share too high?
Can Fite Biopharma's current Net Cash per Share of $3.53 is 41% below median its 10-year median of 5.99. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 30.51. The Biotechnology industry median Net Cash per Share is 5.20. Can Fite Biopharma's value of $3.53 is 32.1% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #63 out of 796 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #63 out of 796 companies for Net Cash per Share. This places Can Fite Biopharma in the top 8% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 5.20. Can Fite Biopharma's value of $3.53 is 32.1% below this benchmark. Historically, Can Fite Biopharma's own Net Cash per Share has ranged from 0.95 to 30.51 over the past decade. While the company's 10-year median is 5.99 vs. the industry median of 5.20, Can Fite Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.20, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Net Cash per Share of $3.53 is 32.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Net Cash per Share is $3.53, which is 41% below median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.10, compared to a current price of $3.31 — trading 45.7% below its estimated fair value. The current Net Cash per Share is $3.53, which is 41% below median its 10-year median of 5.99 and 32.1% below the Biotechnology industry median of 5.20. Can Fite Biopharma's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Net Cash per Share is $3.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.31 is trading 45.7% below its estimated GF Value™ of $6.10.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Net Cash per Share: $3.53 (41% below median its 10-year median of 5.99)
GF Value™: $6.10 vs. price of $3.31 (45.7% below fair value)
Industry Position: 32.1% below the Biotechnology median (#63 of 796)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
46GF Score
Get the complete analysis for CANF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
